Drug Profile
AMG 598
Alternative Names: AMG-598Latest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator Amgen
- Class Monoclonal antibodies; Obesity therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for phase-I development in Obesity in USA (Parenteral)
- 16 Dec 2019 Amgen completes a phase I trial in Obesity in USA (Parenteral) (NCT03757130)
- 26 Feb 2018 Phase-I clinical trials in Obesity in USA (unspecified route) prior to 26/02/2018 (Amgen pipeline, February 2018)